Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Supernus Pharmaceuticals Stock News

SUPNNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$32.45

At close: May 1 EDT

$32.45

0.000.00%

Pre-Market: 4:00 PM EDT

Q1 2025 Earnings in 4 days from now on Tue May 6th, after the market close

Conference call scheduled in 4 days at 16:30 PM Click to view the webcast

Supernus Pharmaceuticals (SUPN) Forecast

News

Earnings Supernus Pharmaceuticals (SUPN) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Latest Supernus Pharmaceuticals Stock News | NASDAQ:SUPN | Benzinga

Get the latest news on Supernus Pharmaceuticals stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Supernus Pharmaceuticals performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, February 26, 2025

Cantor Fitzgerald Reiterates Neutral on Super...
Benzinga Newsdesk - Feb 26, 2025, 8:51AM

Tuesday, February 25, 2025

Supernus Pharmaceuticals Sees FY2025 Sales $6...
Benzinga Newsdesk - Feb 25, 2025, 4:08PM
Supernus Pharmaceuticals Q4 EPS $0.27 Misses ...
Benzinga Newsdesk - Feb 25, 2025, 4:08PM
Earnings Scheduled For February 25, 2025
Benzinga Insights - Feb 25, 2025, 3:32AM

Wednesday, February 19, 2025

This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Avi Kapoor - Feb 19, 2025, 10:38AM
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
Vandana Singh - Feb 19, 2025, 10:29AM
Supernus Pharmaceuticals shares are trading l...
Benzinga Newsdesk - Feb 19, 2025, 9:54AM
Cantor Fitzgerald Downgrades Supernus Pharmac...
Benzinga Newsdesk - Feb 19, 2025, 9:52AM
Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Avi Kapoor - Feb 19, 2025, 8:27AM
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Avi Kapoor - Feb 19, 2025, 7:00AM

Tuesday, February 18, 2025

Supernus Pharmaceuticals shares are trading l...
Benzinga Newsdesk - Feb 18, 2025, 4:36PM
Supernus Reports Results From Phase 2b Study ...
Benzinga Newsdesk - Feb 18, 2025, 4:27PM

Tuesday, February 04, 2025

Supernus Pharmaceuticals shares are trading h...
Benzinga Newsdesk - Feb 4, 2025, 11:40AM
Supernus Receives FDA Approval Of ONAPGO Fr P...
Benzinga Newsdesk - Feb 4, 2025, 9:02AM

Monday, January 27, 2025

Supernus Pharmaceuticals Announces FDA Approv...
Benzinga Newsdesk - Jan 27, 2025, 8:14AM

Tuesday, December 03, 2024

Screening For Black Friday Bargains In The Stock Market
David Pinsen - Dec 3, 2024, 9:21AM

Monday, November 04, 2024

Supernus Pharmaceuticals Sees FY24 Total Reve...
Benzinga Newsdesk - Nov 4, 2024, 4:11PM
Supernus Pharmaceuticals Q3 2024 GAAP EPS $0....
Benzinga Newsdesk - Nov 4, 2024, 4:07PM

Thursday, October 31, 2024

Supernus Pharmaceuticals From A Phase 2 Study...
Benzinga Newsdesk - Oct 31, 2024, 4:16PM

Thursday, October 17, 2024

Supernus Reports Data From Open-Label Phase 2...
Benzinga Newsdesk - Oct 17, 2024, 4:14PM

Wednesday, September 11, 2024

ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
Vandana Singh - Sep 11, 2024, 2:38PM
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Avi Kapoor - Sep 11, 2024, 12:13PM
Supernus Pharmaceuticals shares are trading l...
Benzinga Newsdesk - Sep 11, 2024, 10:39AM
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor - Sep 11, 2024, 9:08AM
Piper Sandler Downgrades Supernus Pharmaceuti...
Benzinga Newsdesk - Sep 11, 2024, 6:41AM

Monday, August 19, 2024

FDA Accepts Supernus Pharmaceuticals' Resubmi...
Benzinga Newsdesk - Aug 19, 2024, 7:03AM

Wednesday, August 07, 2024

Supernus Pharmaceuticals shares are trading h...
Benzinga Newsdesk - Aug 7, 2024, 10:44AM

Tuesday, August 06, 2024

Supernus Raises 2024 Total Revenue Guidance F...
Benzinga Newsdesk - Aug 6, 2024, 4:21PM
Supernus Pharmaceuticals Q2 2024 GAAP EPS $0....
Benzinga Newsdesk - Aug 6, 2024, 4:14PM

Thursday, August 01, 2024

Supernus Resubmits NDA To FDA For SPN-830 Apo...
Benzinga Newsdesk - Aug 1, 2024, 5:30PM

Thursday, May 23, 2024

Supernus Pharmaceuticals Announces Interim An...
Benzinga Newsdesk - May 23, 2024, 4:09PM

Wednesday, May 08, 2024

Supernus Pharmaceuticals Reiterates FY24 Reve...
Benzinga Newsdesk - May 8, 2024, 5:25PM
Supernus Pharmaceuticals Q1 Sales $143.600M M...
Benzinga Newsdesk - May 8, 2024, 5:21PM

Tuesday, May 07, 2024

M8 Pharmaceuticals Signs An Exclusive Licensi...
Benzinga Newsdesk - May 7, 2024, 10:03AM

Monday, April 08, 2024

Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
Vandana Singh - Apr 8, 2024, 10:11AM
Supernus Pharmaceuticals shares are trading l...
Benzinga Newsdesk - Apr 8, 2024, 8:20AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Apr 8, 2024, 8:09AM
Supernus Provides Regulatory Update For SPN-8...
Benzinga Newsdesk - Apr 8, 2024, 8:06AM

Wednesday, February 28, 2024

Piper Sandler Maintains Overweight on Supernu...
Benzinga Newsdesk - Feb 28, 2024, 10:40AM

Tuesday, February 27, 2024

Supernus Sees FY24 Total Revenue $580M-$620M ...
Benzinga Newsdesk - Feb 27, 2024, 5:15PM
Recap: Supernus Pharmaceuticals Q4 Earnings
Benzinga Insights - Feb 27, 2024, 4:30PM
Supernus Pharmaceuticals Q4 2023 Adj EPS $0.3...
Benzinga Newsdesk - Feb 27, 2024, 4:30PM
Earnings Scheduled For February 27, 2024
Benzinga Insights - Feb 27, 2024, 5:01AM

Monday, February 05, 2024

Supernus Pharmaceuticals Wins Infringement An...
Benzinga Newsdesk - Feb 5, 2024, 8:36AM

Tuesday, December 19, 2023

Supernus Pharmaceuticals Has Granted Rights T...
Benzinga Newsdesk - Dec 19, 2023, 7:40AM

Tuesday, December 12, 2023

Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
Vandana Singh - Dec 12, 2023, 2:04PM

Tuesday, November 21, 2023

Board Member at Supernus Pharmaceuticals Exercises Options Worth $203K
Benzinga Insights - Nov 21, 2023, 10:01AM

Friday, November 17, 2023

SVP at Supernus Pharmaceuticals Exercises Options Worth $55K
Benzinga Insights - Nov 17, 2023, 10:00AM

Thursday, November 09, 2023

Piper Sandler Maintains Overweight on Supernu...
Benzinga Newsdesk - Nov 9, 2023, 2:56PM
Supernus Pharmaceuticals shares are trading h...
Benzinga Newsdesk - Nov 9, 2023, 11:31AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved